ReviewJournal of the American Academy of Dermatology2012
Pruritus in cutaneous T-cell lymphoma: a review.
Review in Journal of the American Academy of Dermatology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 81 citations in OpenAlex.
- Pharmacological interventions for pruritus in adult palliative care patients.The Cochrane database of systematic reviews · 2023Pooled it
- Pharmacological interventions for pruritus in adult palliative care patients.The Cochrane database of systematic reviews · 2016Pooled it
- Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma.Leukemia & lymphoma · 2015Trial
- Successful use of nemolizumab for refractory pruritus in cutaneous T-cell lymphoma.JAAD case reports · 2026Article
- Immunopathogenesis of itch: an integrative framework for chronic pruritus.JID innovations : skin science from molecules to population health · 2026Review
- CKD-associated pruritus in haemodialysis: a road map for diagnosis and treatment.Clinical kidney journal · 2025Review
- What's New in Cutaneous T-Cell Lymphoma-Associated Pruritus.American journal of clinical dermatology · 2024Review
- What Is New in Cutaneous T Cell Lymphoma?Current oncology reports · 2023Review
- Mycosis fungoides and Sézary syndrome.Blood research · 2023Review
- Chlormethine gel in combination with other therapies for treatment of mycosis fungoides: a review with patient cases.Frontiers in medicine · 2023Review
- The Skin Microbiome in Cutaneous T-Cell Lymphomas (CTCL)-A Narrative Review.Pathogens (Basel, Switzerland) · 2022Review
- S2k-Guidelines - Cutaneous lymphomas (ICD10 C82 - C86): Update 2021.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2022Article
- Mast cells and tryptase are linked to itch and disease severity in mycosis fungoides: Results of a pilot study.Frontiers in immunology · 2022Article
- Peripheral Mechanisms of Itch.The Journal of investigative dermatology · 2022Review
- Article
- What factors guide treatment selection in mycosis fungoides and Sezary syndrome?Hematology. American Society of Hematology. Education Program · 2021Article
- A Comprehensive Update of the Atypical, Rare and Mimicking Presentations of Mycosis Fungoides.Dermatology and therapy · 2021Review
- Oncostatin M can sensitize sensory neurons in inflammatory pruritus.Science translational medicine · 2021Article
- IL-31, itch and hematological malignancies.Clinical and molecular allergy : CMA · 2021Review
- Neurokinin 1 Receptor Antagonists for Pruritus.Drugs · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
backgroundPruritus can be a distressing and even debilitating symptom for patients with cutaneous T-cell lymphoma (CTCL). To date, few studies have evaluated the pathophysiology of this symptom. Because of this, therapy for pruritus in CTCL has mainly relied on those therapies that target and treat the lymphoma. For patients living with CTCL that relapses or becomes refractory to treatment, and who continue to experience severe itch, this lymphoma-targeted treatment may not be enough to combat their pruritus. Therefore, other itch-targeted therapies are needed for use in this disease.
objectiveWe sought to evaluate the current evidence regarding the mechanism of action and treatments for pruritus associated with CTCL.
methodsAn explicit and thorough search was restricted to all peer-reviewed literature available through MEDLINE (1950 to September 2011) and PubMed. Search terms used were "pruritus," "cutaneous T-cell lymphoma," "CTCL," "mycosis fungoides," "MF," and "Sézary syndrome." All studies that involved pruritus in CTCL, mycosis fungoides, or Sézary syndrome were evaluated by all 3 authors.
resultsThe current literature helps to identify therapies and possible mechanisms for treating patients with CTCL-associated pruritus. LIMITATION: Most studies were preclinical. Only studies involving mechanisms of action or treatment were included.
conclusionA guideline is necessary to assist in the treatment of pruritus in CTCL and additional studies are necessary to uncover the exact mechanism or mechanisms of action.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.